Trial Profile

A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avdoralimab (Primary)
Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms FORCE

Most Recent Events

01 Dec 2022 Results assessing the efficacy and safety of avdoralimab in severe COVID-19, published in the Critical Care Medicine.
06 Jul 2021 According to an Innate Pharma media release, results from this trial, including translational data, are planned to be submitted for publication.
06 Jul 2021 According to an Innate Pharma media release, based on these results, company will stop exploring avdoralimab in COVID-19.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com